Roger C. Carroll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Roger C. Carroll has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Carolyn C. Snider
5 shared publicationsRobert M. Craft
4 shared publicationsDale C. Wortham
2 shared publicationsFengqi Liu
Department of Anesthesiology, Graduate School of Medicine, University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, USA
2 shared publicationsPatrick A. Dakin
2 shared publications- A Audie Smith
Department of Anesthesiology, Graduate School of Medicine, The University of Tennessee Medical Center Knoxville, TN, 37920, USA
1 shared publication
Latest Publications
- 1 February 2013
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 116 (2) , 282-286
A Comparison of VerifyNow® with PlateletMapping® -Detected Aspirin Resistance and Correlation with Urinary Thromboxane
Aspirin-resistant platelet activation in whole blood is attributable to a transcellular pathway not detected by isolated platelet aggregometry. Aspirin resistance as defined by urinary thromboxane levels is associated with increased risk for myocardial infarction or cardiac death. Whole blood point-of-care assays may also detect aspirin resistance. We compared PlateletMapping® with VerifyNow® for detecting aspirin resistance in 200 patients undergoing invasive cardiac procedures. This included 10 patients not receiving aspirin therapy for comparison. The assay results were correlated with urinary 11-dehydro-thromboxane B2 collected 2 to 8 hours after the procedure. PlateletMapping detected aspirin resistance in 32% of patients. VerifyNow detected aspirin resistance in 6% of patients. A patient's compliance with aspirin therapy was confirmed by a <20% aggregation response to arachidonic acid by light transmission aggregometry. Aspirin-resistant patients as determined by PlateletMapping had significantly (P<0.001) higher urinary 11-dehydro-thromboxane B2 levels than aspirin-sensitive patients but significantly (P=0.001) lower levels than patients not receiving aspirin therapy. There was no significant difference in urinary 11-dehydro-thromboxane B2 for aspirin-resistant compared with aspirin-sensitive patients as determined by VerifyNow, but the confidence intervals were wide. There was no significant correlation of resistance as defined by PlateletMapping with aspirin dose. However, there was significant increased aspirin sensitivity with clopidogrel (0.0006) or statin (0.004) cotherapies. There also was a significant correlation of smoking with aspirin resistance. These results indicate that PlateletMapping could be a useful point-of-care assay to identify aspirin-resistant patients for better perioperative risk stratification and management.
- 1 February 2013
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 116 (2) , 282-286
A Comparison of VerifyNow® with PlateletMapping® -Detected Aspirin Resistance and Correlation with Urinary Thromboxane
Aspirin-resistant platelet activation in whole blood is attributable to a transcellular pathway not detected by isolated platelet aggregometry. Aspirin resistance as defined by urinary thromboxane levels is associated with increased risk for myocardial infarction or cardiac death. Whole blood point-of-care assays may also detect aspirin resistance. We compared PlateletMapping® with VerifyNow® for detecting aspirin resistance in 200 patients undergoing invasive cardiac procedures. This included 10 patients not receiving aspirin therapy for comparison. The assay results were correlated with urinary 11-dehydro-thromboxane B2 collected 2 to 8 hours after the procedure. PlateletMapping detected aspirin resistance in 32% of patients. VerifyNow detected aspirin resistance in 6% of patients. A patient's compliance with aspirin therapy was confirmed by a <20% aggregation response to arachidonic acid by light transmission aggregometry. Aspirin-resistant patients as determined by PlateletMapping had significantly (P<0.001) higher urinary 11-dehydro-thromboxane B2 levels than aspirin-sensitive patients but significantly (P=0.001) lower levels than patients not receiving aspirin therapy. There was no significant difference in urinary 11-dehydro-thromboxane B2 for aspirin-resistant compared with aspirin-sensitive patients as determined by VerifyNow, but the confidence intervals were wide. There was no significant correlation of resistance as defined by PlateletMapping with aspirin dose. However, there was significant increased aspirin sensitivity with clopidogrel (0.0006) or statin (0.004) cotherapies. There also was a significant correlation of smoking with aspirin resistance. These results indicate that PlateletMapping could be a useful point-of-care assay to identify aspirin-resistant patients for better perioperative risk stratification and management.
- 1 April 2010
- Published by Elsevier in Thrombosis Research
- Vol. 125 (4) , e118-e122
Post interventional cardiology urinary thromboxane correlates with PlateletMapping® detected aspirin resistance
- 1 April 2010
- Published by Elsevier in Thrombosis Research
- Vol. 125 (4) , e118-e122
Post interventional cardiology urinary thromboxane correlates with PlateletMapping® detected aspirin resistance
- 1 July 2009
- Published by Elsevier in Translational Research
- Vol. 154 (1) , 34-39
Early evaluation of acute traumatic coagulopathy by thrombelastography
- 1 July 2009
- Published by Elsevier in Translational Research
- Vol. 154 (1) , 34-39
Early evaluation of acute traumatic coagulopathy by thrombelastography
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (3) , 367-370
Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (3) , 367-370
Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients
- 1 April 2006
- Published by Elsevier in Journal of Laboratory and Clinical Medicine
- Vol. 147 (4) , 197-204
Correlation of perioperative platelet function and coagulation tests with bleeding after cardiopulmonary bypass surgery
- 1 April 2006
- Published by Elsevier in Journal of Laboratory and Clinical Medicine
- Vol. 147 (4) , 197-204
Correlation of perioperative platelet function and coagulation tests with bleeding after cardiopulmonary bypass surgery
- Open Access
- 1 January 2003
- Published by Springer Nature in BMC Anesthesiology
- Vol. 3 (1) , 3
A randomized, placebo controlled, trial of preoperative sustained release Betamethasone plus non-controlled intraoperative Ketorolac or Fentanyl on pain after diagnostic laparoscopy or laparoscopic tubal ligation [ISRCTN52633712].
Gynecological laparoscopic surgery procedures are often complicated by postoperative pain resulting in an unpleasant experience for the patient, delayed discharge, and increased cost. Glucocorticosteroids have been suggested to reduce the severity and incidence of postoperative pain. This study examines the efficacy of a sustained release betamethasone preparation to reduce postoperative pain and the requirement for pain relief drugs after either diagnostic laparoscopy or tubal ligation. Patients were recruited, as presenting, after obtaining informed consent. Prior to surgery, patients were randomly selected by a computer generated table to receive either pharmacy-coded betamethasone (12 mg IM Celestone™) or an optically identical placebo injection of Intralipid™ and isotonic saline mixture. The effect of non-controlled prophylactic intraoperative treatment with either fentanyl or ketorolac per surgeon's orders was also noted in this study. Blood samples taken at recovery and at discharge times were extracted and analyzed for circulating betamethasone. Visual analog scale data on pain was gathered at six post-recovery time points in a triple blind fashion and statistically compared. The postoperative requirement for pain relief drugs was also examined. Although the injection achieved a sustained therapeutic concentration, no beneficial effect of IM betamethasone on postoperative pain or reduction in pain relief drugs was observed during the postoperative period. Indeed, the mean combined pain scores during the 2 hour postoperative period, adjusted for postoperative opioids as the major confounding factor, were higher approaching statistical significance (P = 0.056) in the treatment group. Higher pain scores were also observed for the tubal ligation patients relative to diagnostic laparoscopy. Intraoperative fentanyl treatment did not significantly lower the average pain score during the 2 hour postoperative period. Intraoperative ketorolac treatment significantly lowered (P = 0.027) pain scores and reduced the postoperative requirement for additional pain relief drugs. There was a lack of efficacy of preoperative sustained release betamethasone in reducing postoperative pain despite maintaining a therapeutic concentration during the postoperative period. Intraoperative Ketorolac did afford some short-term pain relief in the postoperative period and reduced the need for additional pain relief drugs.
- 1 January 2003
- Published by Springer Nature in BMC Anesthesiology
- Vol. 3 (1) , 3
Open AccessA randomized, placebo controlled, trial of preoperative sustained release Betamethasone plus non-controlled intraoperative Ketorolac or Fentanyl on pain after diagnostic laparoscopy or laparoscopic tubal ligation [ISRCTN52633712].
Gynecological laparoscopic surgery procedures are often complicated by postoperative pain resulting in an unpleasant experience for the patient, delayed discharge, and increased cost. Glucocorticosteroids have been suggested to reduce the severity and incidence of postoperative pain. This study examines the efficacy of a sustained release betamethasone preparation to reduce postoperative pain and the requirement for pain relief drugs after either diagnostic laparoscopy or tubal ligation. Patients were recruited, as presenting, after obtaining informed consent. Prior to surgery, patients were randomly selected by a computer generated table to receive either pharmacy-coded betamethasone (12 mg IM Celestone™) or an optically identical placebo injection of Intralipid™ and isotonic saline mixture. The effect of non-controlled prophylactic intraoperative treatment with either fentanyl or ketorolac per surgeon's orders was also noted in this study. Blood samples taken at recovery and at discharge times were extracted and analyzed for circulating betamethasone. Visual analog scale data on pain was gathered at six post-recovery time points in a triple blind fashion and statistically compared. The postoperative requirement for pain relief drugs was also examined. Although the injection achieved a sustained therapeutic concentration, no beneficial effect of IM betamethasone on postoperative pain or reduction in pain relief drugs was observed during the postoperative period. Indeed, the mean combined pain scores during the 2 hour postoperative period, adjusted for postoperative opioids as the major confounding factor, were higher approaching statistical significance (P = 0.056) in the treatment group. Higher pain scores were also observed for the tubal ligation patients relative to diagnostic laparoscopy. Intraoperative fentanyl treatment did not significantly lower the average pain score during the 2 hour postoperative period. Intraoperative ketorolac treatment significantly lowered (P = 0.027) pain scores and reduced the postoperative requirement for additional pain relief drugs. There was a lack of efficacy of preoperative sustained release betamethasone in reducing postoperative pain despite maintaining a therapeutic concentration during the postoperative period. Intraoperative Ketorolac did afford some short-term pain relief in the postoperative period and reduced the need for additional pain relief drugs.
- 1 May 2002
- Published by Elsevier in Thrombosis Research
- Vol. 106 (4-5) , 199-203
Demonstration of an activation regulated NF-κB/I-κBα complex in human platelets
- 1 May 2002
- Published by Elsevier in Thrombosis Research
- Vol. 106 (4-5) , 199-203
Demonstration of an activation regulated NF-κB/I-κBα complex in human platelets
- 1 November 2001
- Published by Elsevier in Thrombosis Research
- Vol. 104 (4) , 239-247
Synergistic Outside–In Regulation of Platelet Activation by GPIIb/IIIa Ligand-Induced Conformation and Oligomerization
- 1 November 2001
- Published by Elsevier in Thrombosis Research
- Vol. 104 (4) , 239-247
Synergistic Outside–In Regulation of Platelet Activation by GPIIb/IIIa Ligand-Induced Conformation and Oligomerization